The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
the efficient construction of three-dimensional bisindolines via oxidative coupling cyclization in an intermolecular manner. This reaction is featured by its operational simplicity, metal-free conditions, lack of protecting group, and high selectivity. Notably, a wide range of anilines are suitable in this intermolecular cyclization, furnishing corresponding bisindolines in up to 98% yield.